Iberdomide
- Generic Name
- Iberdomide
- Drug Type
- Small Molecule
- Chemical Formula
- C25H27N3O5
- CAS Number
- 1323403-33-3
- Unique Ingredient Identifier
- 8V66F27X44
- Background
Iberdomide (CC-220) has been used in trials studying the treatment of Systemic Lupus Erythematosus.
Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study
- Conditions
- Plasma Cell Myeloma
- Interventions
- First Posted Date
- 2022-05-26
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 49
- Registration Number
- NCT05392946
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT)
- First Posted Date
- 2022-04-29
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 16
- Registration Number
- NCT05354557
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge (Consent and Followup), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (Consent and Follow-Up only), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen (Consent and Follow up), Montvale, New Jersey, United States
Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2022-03-21
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- iTeos Belgium SA
- Target Recruit Count
- 16
- Registration Number
- NCT05289492
- Locations
- 🇺🇸
Fred Hutchinson Cancer Center, Seattle, Washington, United States
🇺🇸Eastern Connecticut Hematology & Oncology, Norwich, Connecticut, United States
🇧🇪ZNA Cadix, Antwerp, Belgium
Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients
- Conditions
- Multiple Myeloma
- First Posted Date
- 2022-03-09
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Canadian Myeloma Research Group
- Target Recruit Count
- 75
- Registration Number
- NCT05272826
- Locations
- 🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada
🇨🇦London Health Sciences Centre, London, Ontario, Canada
Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2022-01-20
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Hackensack Meridian Health
- Target Recruit Count
- 66
- Registration Number
- NCT05199311
- Locations
- 🇺🇸
Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
🇺🇸John Theurer Cancer Center, Hackensack, New Jersey, United States
Iberdomide Maintenance Therapy in Patients With Multiple Myeloma
- First Posted Date
- 2022-01-04
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 40
- Registration Number
- NCT05177536
- Locations
- 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
- Conditions
- Non-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2021-12-27
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 121
- Registration Number
- NCT05169515
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
🇮🇱Hadassah Medical Center, Jerusalem, Israel
🇮🇱Sourasky Medical Center, Tel-Aviv, Israel
A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse."
- Conditions
- Multiple Myeloma at First Relapse
- Interventions
- First Posted Date
- 2021-08-10
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- Nantes University Hospital
- Target Recruit Count
- 75
- Registration Number
- NCT04998786
- Locations
- 🇫🇷
CH de la cote basque, Bayonne, France
🇫🇷CHRU Hopital Haut Lévêque, Bordeaux, France
🇫🇷CHU, Toulouse, France
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2021-07-26
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Celgene
- Target Recruit Count
- 864
- Registration Number
- NCT04975997
- Locations
- 🇨🇦
Local Institution - 108, Quebec, Canada
🇨🇳Local Institution - 136, Guangzhou, China
🇨🇳Local Institution - 128, Hangzhou City, China
Study to Evaluate Safety and Tolerability of Iberdomide (CC-220) in Participants With Kidney Impairment Compared to Participants With Normal Kidney Function
- First Posted Date
- 2021-06-22
- Last Posted Date
- 2023-02-15
- Lead Sponsor
- Celgene
- Target Recruit Count
- 26
- Registration Number
- NCT04933747
- Locations
- 🇺🇸
Local Institution - 002, Knoxville, Tennessee, United States
🇺🇸Local Institution - 003, San Antonio, Texas, United States
🇺🇸Local Institution - 001, Orlando, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.